REGN5458 is a bispecific BCMA/CD3 T cell engaging antibody.
| SparkCures ID | 351 |
|---|---|
| Developed By | Regeneron Pharmaceuticals |
| Generic Name | REGN5458 |
| Treatment Classifications | |
| Treatment Targets |
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.